Targeting EBV-associated lymphomas

NIH RePORTER · NIH · U01 · $645,012 · view on reporter.nih.gov ↗

Abstract

ABSTRACT Epstein-Barr Virus (EBV) is the etiological agent of several hematopoietic malignancies including multiple types of non-Hodgkin lymphoma (NHL). These EBV-positive NHL subtypes are comprised of post-transplant lymphoproliferative disease (PTLD), diffuse large B cell lymphomas (DLBCL), T cell lymphomas, Natural killer (NK)/T cell lymphoma (NKTL), and Burkitt's lymphoma (BL). Our studies have found that FAM72A is highly expressed in EBV-positive lymphomas and contributes to EBV-mediated lymphomagenesis, which gives rise to EBV-positive NHL. In response to PAR-21-348, we propose to address how EBV’s upregulation of FAM72A contributes to the development of EBV-driven NHL.

Key facts

NIH application ID
11001649
Project number
1U01CA294800-01
Recipient
UNIV OF NORTH CAROLINA CHAPEL HILL
Principal Investigator
BLOSSOM A DAMANIA
Activity code
U01
Funding institute
NIH
Fiscal year
2024
Award amount
$645,012
Award type
1
Project period
2024-09-10 → 2029-08-31